Anne R Meibohm - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Anne R Meibohm

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.

The New England Journal of Medicine|July 25, 2008

Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.

The New England Journal of Medicine|July 25, 2008

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.

The New England Journal of Medicine|July 25, 2008

Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.

The New England Journal of Medicine|July 25, 2008

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.

Pageof 2